NCT00638976已完成3 期
INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial
Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 91
- 试验地点
- 1
研究概览
简要总结
Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20 enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK).
详细描述
The Objective of the trial is compare the efficacy and, secondarily, the safety and effectiveness of pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide in comparison to placebo in patients with diffuse CAD undergoing multiple DES implantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Candidates for this study must meet all of the following criteria:
- •Male or female able to understand and sign a witnessed informed consent
- •Age ≥ 18 yo
- •Patients with stable (CCS 1-4) or unstable angina pectoris (but with the most recent anginal episode occurring >48 hours before the procedure) or documented silent ischemia
- •Stable Hemodynamic conditions (systolic BP > 100 HR > 40 < 100).
- •No clinical and ECG changes suggestive of ongoing acute or recent (<48 hours) myocardial infarction.
- •Angiographic evidence of a de novo lesion > 50% requiring implantation of two DES in overlapping with a total stent length > 33 mm and reference vessel diameter between 2.5 and 4.0 mm (by visual estimation) in one coronary vessel. Multiple lesions in the same vessels can be included but at least one lesion should require implantation of two DES in overlapping with a total stent length > 33 mm. The definition of multivessel disease requires an intention to treat at least two lesions (with a least one with the characteristics reported above) in two different major epicardial segments. For example, the presence of a lesion in the left anterior descending artery and in the obtuse marginal or the presence of a lesions in the right postero-lateral branch and in a diagonal branch will qualify as multivessel. The presence of lesions in the left anterior descending artery and in the diagonal branch will not qualify as multivessel. Bifurcation lesions and ostial lesions can be included, but only if at least two DES in overlapping with a total stent length > 33 mm are implanted in the same branch. When treating diffuse lesion in the same vessel, overlapping stenting is recommended with high pressure (>14 atm post-dilation) of the overlap zone. There is no maximum stent length to treat one coronary vessel.
排除标准
- •Female sex with childbearing potential
- •Age <18 years
- •Ongoing or recent episode (<48 hours) of unstable coronary artery disease (including both ST-elevation and non-ST-elevation acute coronary syndromes)
- •Administration of any GP IIb/IIIa inhibitors during the previous 2 weeks
- •Serum creatinine >2.5 mg/dl or with a creatinine clearance <40mL/min
- •Ongoing serious bleeding or bleeding diathesis
- •Previous stroke in the last 6 months
- •Major surgery within the previous 6 weeks
- •Platelet count <100,000 per mm3
- •Ejection Fraction below 30%
- •The patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or sensitivity to contrast which cannot be adequately pre-medicated.
- •Hemodynamic instability (systolic blood pressure < 100 mm Hg; heart rate < 40 bpm or >100 bpm; complex ventricular arrhythmias; AV block) requiring balloon counterpulsation or inotropic support.
- •The patient is simultaneously participating in another device or drug study. Patient must have completed the follow-up phase of any previous study at least 30 days prior to enrolment in this study.
- •Positive clinical history for intracranial neoplasia, AV malformation, aneurysm.
- •INR ≥ 2.0 or prothrombin time 1.2 times upper limit of normality
- •Clinically manifested reduced liver function
- •Programmed surgery within six months
- •Angiographic Exclusion Criteria:
- •DES implantation in a chronic total occlusion or for the treatment of in-stent restenosis.
- •Treatment of lesions where the operator feels necessary the usage of rotactional atherectomy
- •Vessel size < 2.25 mm or > 5 mm (by visual estimation).
- •Previous implantation of a bare/DES in the target lesion
研究组 & 干预措施
1.Integrilin, GSK
Other
Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
干预措施: eptifibatide (Drug)
2
Placebo Comparator
Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
干预措施: placebo (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
INtegrilin plus STenting to Avoid Myocardial Necrosis Trial - INSTANTEUCTR2007-002617-39-ITFondazione Mediolanum Onlus
进行中（未招募）
不适用
Integrilin plus stenting to avoid myocardial necrosis trial. Pilot Study - NDpatients with diffuse CAD undergoing percutaneous treatment on a native coronary vassel with planned implantation of 33 mm of DES with reference vessel diameter 2.25-4.0 mm.MedDRA version: 6.1Level: PTClassification code 10011076EUCTR2006-003684-32-ITOSPEDALE S. RAFFAELE320
已完成
2 期
Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable AnginaCardiovascular DiseasesNCT02529189Queen Mary University of London300
已完成
2 期
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their InfantsRespiratory Syncytial Virus InfectionsNCT04126213GlaxoSmithKline534
已完成
不适用
Multicenter, randomized trial of intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary PCI.Acute myocardial infarctionNL-OMON27593Interuniversity Institute of Cardiology of the Netherlands (ICIN), Utrecht, the Netherlands200